FDA Approves Companion Diagnostic for Colorectal Cancer Treatment
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
